hemostastis pada anak
DESCRIPTION
TRANSCRIPT
![Page 1: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/1.jpg)
Hemostasis DiseaseIn Children
dr. Bertha
![Page 2: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/2.jpg)
• Vascular response• Plateletadhesion• Platelet aggregation• Clot formation• Clot stabilization• Limitation of clotting (antitrombil III, Protein C,
Protein S, TFP1)• Re-establishment of vascular potency
Fibrinolusis & vascular healing
Hemostatic Mechanism
![Page 3: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/3.jpg)
History
• Site, severity,duration of bleeding• Age of the symtomp onset• Spontaneous or after trauma• Previous history or family historyof bleeding• Does bruising (memar) occur spontaneously?• IS there has been previous surgery or dental
procedure?• Menstrual history
![Page 4: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/4.jpg)
• Symptoms primarily associated with mucous or skin (mucocutaneous bleeding) defects in platelet or blood vessel wall interaction (vWF disease)
• Or muscle & joints bleeding (deep bleeding) clotting factor deficiency
• Presence of petechiae, ecchymoses, hematomas, hemarthroses, or mucous bleeding
Physical examination
![Page 5: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/5.jpg)
-Platelet count-Bleeding time
-PT / aPTT
Normal
Ab Normal
Trombin time vWF
Specific work-up
![Page 6: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/6.jpg)
• Bleeding time (BT)– Assesses platelet function & their interaction with vascular wall– Platelet < 100.000/µL prolonged BT– Disproportionate BT qualitative platelet defects or vWF
disease
• aPTT– Measures the initiation of clotting (intrinsic pathway)– doesn’t measure factor VII, XIII or anticoagulant
• PT– Measures extrinsic pathway– Normal in defiencies offactor VIII, IX, XI or XIII
Laboratory
![Page 7: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/7.jpg)
• TT– Measures final step of the clotting cascade– Prolonged reduced fibrinogen levels
• Dysfunctional fibrinogen (hypo/afibrinogenemia)• Substances that interfere with fibrin polymerization (heparin or fibrin
split products) reptilase time
• Mixing studies– if there is unexplained prolongation of PT, PTT or TT– Normal plasma + patient’s plasma repeat lab exam
• Correction of PT/PTT by mixing clootting factor deficiencie• Not corrected + bleeding inhibitor• Not corrected, no bleeding lupus-like-anticoagulant
• Clotting factor assays
Laboratory
![Page 8: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/8.jpg)
Hemophilia
• Hemophilia A Factor VIII deficiencies (85%)
• Hemophilia B Factor IX deficiencies ( 10-15%)
• Most common & serious congenital coagulation factor deficiencies
• Prevalence 1:5000 males• No racial predilection• Clinical finding same
![Page 9: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/9.jpg)
Hemophilia
• Classification– Severe deficiency <1% factor activity
• Spontaneous bleeding
– Moderate deficiency 1-5% factor activity• Mild trauma to induce bleeding
– Mild deficiency >5% factor activity• May be asymptomatic, took years to diagnose
![Page 10: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/10.jpg)
Hemophilia
• Clot formation is delayed & fragile• When bleeding occurs in the closed space
tamponade• Open wound profuse bleeding• Bleeding symptoms may be present in utero• Neonates intracranial bleeding• Easy bruising, IM hematomas, hemarthroses• Bleeding from minor trauma of the mouth
persist for days
![Page 11: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/11.jpg)
![Page 12: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/12.jpg)
Hemophilia
• Iliposoas bleeding life threatening– Inability to extend the hip– Confirmed by UTZ or CT scan– Aggresive therapy
• Life threathening bleeding– CNS, Upper airways bleeding– External bleeding– GI bleeding
![Page 13: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/13.jpg)
Hemophilia
• Prolonged PTT
• Factor assay:– Severe def.– Moderate def.– Mild def.
• Inhibitor assay
![Page 14: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/14.jpg)
![Page 15: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/15.jpg)
Treatment
• Prevention of trauma• Phychosocial• Avoid aspirin & NSAID• Replacement therapy
– Recombinant fact. VIII/IX– Cryoprecipitate/ cryosupernate
• Joint bleeding:– Ice pack– Elevate the limb– Immobilization of the limb
• Supportive therapy• multidiciplinary
![Page 16: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/16.jpg)
Chronic Complication
• Chronic joint destruction
• Risk of transfusions associated disease
• Development of inhibitor
![Page 17: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/17.jpg)
Disseminated Intravascular Coagulation (DIC)
• Consumptive coagulopathy
• Consumption of clotting factors, platelets & anticoagulant protein
• Widespread intavascular deposition of fibrin tissue ischemic & necrosis, generalized hemorrhagic state, hemolytic anemia
![Page 18: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/18.jpg)
DIC
• Trigger factors:– Hypoxia– Acidosis– Tissue becrosis– Shock– Endothelial damage– Septic shock– Incompatible blood transfusion– Snake bite
![Page 19: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/19.jpg)
DIC
• Manifestations:– Bleeding from surgical incision/venipuncture
(pungsi vena)petechiae, ecchymoses– Organ damage– Anemia microangiopathic hemolytic anemia
![Page 20: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/20.jpg)
DIC
• Labs:– Prolonged PT, PTT & TT– Thrombocytopenia– Hemolytic process on blood smear– FDP, d-dimer appear in blood
![Page 21: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/21.jpg)
DIC
• Treatment:– Treat the cause– Restore normal homeostasis
• Correct shock, acidosis, hypoxia
– Blood component transfusions• Platelet concentrate, cryoprecipitate, FFP
– Heparin infusions• For acute promyelocytic leukemia• Not indicated for septic shock, snack bite, massive
head injury, incompatible transfusions
![Page 22: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/22.jpg)
Platelet
![Page 23: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/23.jpg)
• Size: 1-4 µm (younger platelets are larger)• Mean platelet volume (MPV) : 8,9 ± 1.5 µm3
• Number : 150.000 – 400.000 / mm• Distribution : 1/3 in the spleen, 2/3 in blood
stream• Life span : 7-10 days
Bleeding may occur because :• Reduce in number (thrombsytopenia)• Defective in function
The characteristic of platelets
![Page 24: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/24.jpg)
Macrothrombocytes (MPV ↑)• ITP or condition with increased
platelet turnover (eg. DIC)
• Bernard-Soulier Syndrome
• May Heggin anomaly and other MYH-9-Related disease
• Swiss Cheese platelet syndrome
• Montreal platelet syndrome
• Gray platelet syndorme
• Various mucopolysaccharisoses
Microthrombocytes (MPV ↓)• Wiskott –Aldrich syndrome
• TAR syndrome
• Some storage pool diseases
• Iron def. Anemia
Normal size (MPV normal)• Disease with hypocellular marrow
or infiltrated with malignant disease
Thrombocytopeni based on pletelet sized
![Page 25: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/25.jpg)
Clasification of Trombocytopenia
Incrase platelet destruction
Disorder of platelet distribution or
pooling
Decrased platelet production
Pseudothrombocytopenia
Thrombocytopenia
![Page 26: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/26.jpg)
Clasification of Trombocytopenia
Disorder of platelets
distribution or pooling
Hypersplenism(Portal hypertension,
Gaucher disease,cyanitic congenital, heart disease,
neoplasm, infection)
Hypothermia
![Page 27: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/27.jpg)
Clasification of Trombocytopenia
Decrase plateletproduction
Hyperplasia or suppresion of megakaryocyte
MarrowInfiltrativeProcess
Drugs:Chlorothiazide, ethanol
Constitusional:Rubella,…
Ineffective Thrombopoeisis:……..
Disorder of control mechanism:
Trombopoetin deficiency
Acquired myelositic disorder:
Drugs
Benign:Osteoporosis
Malignancy
![Page 28: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/28.jpg)
Clasification of Trombocytopenia
Pseudo-thrombocytopenia
Platelet inactivationduring bloofcollection
Undercounting ofmegathrombocytes
In vitro agglutinationof platelets to EDTA
![Page 29: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/29.jpg)
Clasification of Trombocytopenia
Increase plateletdestruction
Non-immuneThrombocytopenia
ImmuneThrombocytopenia
Idiopathic (ITP)
Secondary:Infection, drugs,
SLE, etc
Neonatal:Autoimune, Erito-blastosis fetalis
Platelet consumption
Platelet destruction:
drugs
![Page 30: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/30.jpg)
Immune Thrombocytopenia
The most frequent cause of thrombocytopenia is immune mediated platelet destruction due to:
1. autoantibodies
2. drug-dependent antibodies
3. alloantibodies
![Page 31: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/31.jpg)
A syndrome characterized by thrombocytopenia :
1. Shortened platelet survival
2. Presence of antiplatelet antibody in the plasma
3. Increase megakaryocytes in the bone marrow
Immune (Idiopathic) Thrombocytopenic Pupura
![Page 32: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/32.jpg)
ITP
• The syndrome can be:– Acute
• Platelet count return to normal within 6 month & relaps does not occur
• Most in children– Chronic
• Platelet count remain low beyond 6 month• More common in adult
– Recurrent• Platelet count decrease after having returned to
normal
![Page 33: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/33.jpg)
Predisposing Factor
• 50-80% : infection (usually viral) prior to thrombocytopenia
• About 20% : a specific infection can be identified, eg. Rubella, measel, varicella, pertussis, mumps, infectious mononucleosis, CMV, parvovirus or bacterial
• Measel or smallpox vaccination
![Page 34: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/34.jpg)
Clinical Manifestation
• Skin: Ecchymosess/purpira usually on the anterior surface of lower extremities and body prominences (ribs, scapula, shoulders, legs, pubic)
• Mucous membranes: subconjunctival, buccal mucosa, soft palate
• Menorrhagia• Hematemesis & melena infrequent• Others: nose, gum, G.I, Kidnets (usually at the
onset of the disease
![Page 35: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/35.jpg)
Clinical manifestation
• Intracranial bleeding:– Usually preceded by:
• Headache, dizziness, acute bleeding at other place
• Retinal hemorrage
• Middle ear hearing impairment
• Deep muscle hematoma and hemarthrosis• Rare, seen after i.m injection or significant trauma• Characteristic of plasma coagulation
![Page 36: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/36.jpg)
Laboratory Findings
• Low platelet count– Always <150.000 /mm3
– Often <20.000 /mm3 in patients with severe generalized hemorrhagic manifestations
– MPV ( N : 8.9 + 1.5 um3)• Blood smear
– Thormbocytopenia must be confirmed by peripheral blood examination to exclude the diagnosis pseudothrombocytopenia, the presence of megathrombocytes and other hematologic manifestation
– Blood semar normal apart from thrombicytopenia• Anemia present in proportion to amount of blood loss
![Page 37: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/37.jpg)
Bone Marrow Aspiration
• Indication– Atypical presentation– Poor respone to therapy– To exclude other hematologic disorder sucg as
leukemia
• Characteristic – ↑ ,megakaryocytes, immature and asence of budding– Nomlar erythroid and myeloid cells– Occasionally eosinophilia– Erythroid hyperplasia if significant blood loss
![Page 38: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/38.jpg)
Intracranial Hemorrhage
• Incidence : 0,1 – 0,5 %• Age: 13 month – 16 years• Platelet count :
– < 10.000 /mm3 in 73% cases– 10-20.000 /mm3 in 25% of cases– >20.000 /mm3 in 2% of cases
• Interval between diagnosis of ITP and ICH:– <4 wekks in 51% of cases– 4 weeks – 9 years in 49%of cases (mean 27 weeks)
![Page 39: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/39.jpg)
Intracranial Hemorrhage
• Risk Factors in 45 % cases of ICH include:– Head injury (29%)– Aspirin treatment (5%)– AV malformation (17%)– Mucocutaneous hemorrhage (49%)
• Site of ICH:– Intra cerebral (77%)– Subdural hematoma (23%)
• 50 % had prior tretament with steroid and / or IVIG
• 54% survival, most without permanent damage
![Page 40: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/40.jpg)
Supportive Treatment
• No treatment is required when platelet count >20.000 /mm3 , asymptomatic or has mild bruising but no evidence of mucous membrane bleeding
• Competitive sport should be avoided• Depoprovera or any other long-acting
progesteron in suspending menstruation for several month
• Aspirin, Nonsteroidal antiinflammatory agents and any other drug the interfere with platelet function should not be given
![Page 41: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/41.jpg)
Farmacological Treatment
• Treatment choice : Steroid, IVIG, and anti–D
• Indication– Platelet count <20.000 /mm3 and significant
mucous membrane bleeding– Platelet <10.000 /mm3 and minor purpura
![Page 42: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/42.jpg)
Steroid Therapy• Mechanisms:
– Inhibits phagocytosis of antibody coated platelet in the spleen prolongs platelet survival
– Improves capillary resistance and thereby improve platelet economy
• Dose and Duration:– Dose : 2mg/kg/day (max. 60/mg/day) in divided dose. Tap
off in 5-7 day interval and stopped at the end of 21-28 days, regardless of the response
– In severe cases methylprednisolone 30mg/kg/day (max 1 g/day) for 3 days
• Prolonged case of steroid in undesirable:– Worsen the thrombocytopenia and depress platelet
[rpduction– Side effect : weight gain, caushingoid facies, fluid retention,
acne, hyperglycemia, hypertension, mood swings, pseudotumor cerebri, cataracts, growth retradation , avascular necrosis
![Page 43: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/43.jpg)
IVIG
• Mechanism of action– Reticuloendothelial Fc-receptor blockade– Activation of inhibitor pathways– Decrease autoantibody synthesis
• Indication– Neonatal Symptomatic Immune Thrombocytopenia
Infant less than 2 y.o are generally more refractory to steroid treatment
– Alternative therapy to corticosteroid therapy
• Much more expensive and has significant side effects
![Page 44: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/44.jpg)
Anti –D Therapy
• Plasma derived gamma immune globulin of anti –Rh antigen
• Mechanism action :– Blockade of Fc receptor of reticuloendothelial cell
• Platelet is increase after 48 hours, therefore the therapy is not appropriate for emergency treatment
• Patients who have not undergone splenectomy and Rh positive are more likely to respond to IV Anti-D
![Page 45: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/45.jpg)
Splenectomy
• Indication– Severe acute ITP with acute life-threatening bleeding
and not responsive to medical treatment– Chronic ITP with bleeding symptom or platelet count
persistently below 30.000 /mm3 an not responsive to medical treatment for several years
– In very active patient subject to frequent trauma, early splenectomy may be indicated
• Because the hazard of overwhelming postsplenectomy infection (OPSI) the procedure should be performed after clear indication
![Page 46: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/46.jpg)
Splenectomy
• Indication for splenectomy are rare because of judicious use if steroid and IVIG
• It is rarely necessary to perform splenectomy before 2 years adter diagnosis
• Laparoscopic splenectomy is preferable to open splenectomy
• Up to 70% have complete and long-lasting recovery
• 40% wuth persistent thrombocytopenia after splenectomy have acsseory spleen
![Page 47: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/47.jpg)
Treatment Algorithm
Yang skema itu.. Gak keliatan di foto.. Maaf ya kawan..
![Page 48: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/48.jpg)
Live Threatening Hemorrahage
• Platelet transfusion
• Methylprednisolone 500 mg/m2 IV per day for 3 days
• IVIG 2 /kg for 12 hours infusion
• Emergency splenecomy
![Page 49: Hemostastis Pada Anak](https://reader033.vdocuments.us/reader033/viewer/2022061116/5466161eaf795974338b510a/html5/thumbnails/49.jpg)
Prognosis• Excellent, 50 % recover within 1 month % 70-80% within 6
month
• Spontaneous remission after 1 year in uncommon, but may occur even after several years
• When demonstration underlying cause, the prognosis is related to the cause
• Age older than 10 years, insidious onset, female are associated with chronic ITP
• 50-60 % chronic ITP………….. without any other therapy and without splenectomy